aflibercept

FDA Drug Profile — ENZEEVU, EYLEA, EYLEA HD

aflibercept is listed in the FDA National Drug Code directory with 13 NDC codes, marketed under brand names including ENZEEVU, EYLEA, EYLEA HD. Available dosage forms: injection, solution, injection.

Drug details

Generic Name
aflibercept
Brand Names
ENZEEVU, EYLEA, EYLEA HD
Application Number
BLA761382
Sponsor
Regeneron Pharmaceuticals, Inc
NDC Codes
13
Dosage Forms
INJECTION, SOLUTION, INJECTION
Routes
INTRAVITREAL
Active Ingredients
AFLIBERCEPT, AFLIBERCEPT-YSZY

Indications and Usage

1 INDICATIONS AND USAGE EYLEA is indicated for the treatment of: EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Retinopathy of Prematurity (ROP) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Retinopathy of Prematurity (ROP)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.